The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Ixazomib in combination with daratumumab and dexamethasone for the treatment of RRMM
|
Ixazomib, an oral proteasome inhibitor, is approved in combination with lenalidomide and dexamethasone for the treatment of MM after ≥1 prior therapy. However, lenalidomide is also commonly used in the first-line and lenalidomide-refractory disease is frequent, highlighting the need for lenalidomide-free alternatives in the relapsed/refractory setting. Data from a phase II study (NCT03439293) evaluating ixazomib in combination with daratumumab and dexamethasone (IDd) in RRMM, including those with hard-to-treat and lenalidomide-refractory disease, were presented in the American Journal of Hematology by Delimpasi et al.1
|
| Key learnings: |
|
At the final analysis of this phase II trial, ORR was 64.4%, with a ≥VGPR of 30.5% in response-evaluable patients treated with IDd (n = 59). |
|
Response rates among the subgroups analyzed were 53.3% in patients with high-risk cytogenetics, 58.3% in patients with expanded high-risk cytogenetics, 50.0% in patients aged ≥75 years, and 61.9% in lenalidomide-refractory patients. |
|
The median PFS for patients treated with IDd was 16.8 months. Median PFS was comparable in those with high-risk cytogenetics (8.7 months) and in those refractory to lenalidomide (12.6 months). |
|
54.1% of patients experienced Grade ≥3 TEAEs, with 1.6% of patients having Grade ≥3 peripheral neuropathy. |
|
TEAEs led to dose modifications, reductions, and discontinuations in 62.3%, 36.1%, and 16.4% of patients, respectively. |
|
Data presented highlight the IDd regimen as a tolerable treatment option for patients with RRMM, including for those with high-risk features. As an all-oral, lenalidomide-free option, it provides an alternative for potentially difficult to treat patients. |
Abbreviations: IDd, ixazomib-daratumumab-dexamethasone; MM, multiple myeloma; ORR, overall response rate; PFS, progression-free survival; RRMM, relapsed/refractory multiple myeloma; TEAE, treatment-emergent adverse events; VGPR, very good partial response.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content